|
typ |
publikacja |
3 |
Czasopismo |
Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212. |
59 |
Czasopismo |
Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196. |
84 |
Czasopismo |
Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499. |
99 |
Czasopismo |
Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
169 |
Czasopismo |
Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363. |
182 |
Czasopismo |
Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60. |
244 |
Czasopismo |
Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913. |
249 |
Czasopismo |
Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045. |
251 |
Czasopismo |
Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713. |
289 |
Czasopismo |
Jim LK. Physical and chemical compatibility of intravenous ciprofloxacin with other drugs. Ann Pharmacotherapy 1993 ; 27: 704-707. |
299 |
Czasopismo |
Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741. |
300 |
Czasopismo |
Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292. |
301 |
Czasopismo |
Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300. |
307 |
Czasopismo |
Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799. |
335 |
Czasopismo |
Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406. |
367 |
Czasopismo |
Thompson DF, Allen LV, Desai SR, Rao PS. Compatibility of furosemide with aminoglycoside admixtures. Am J Hosp Pharm 1985 ; 42: 116-119. |
421 |
Czasopismo |
Foley PT, Bosso JA, Bair JN, Townsend RJ. Compatibility of clindamycin phosphate with cefotaxim sodium or netilmicin sulfate in small-volume admixtures. Am J Hosp Pharm 1985 ; 42: 839-843. |
492 |
Czasopismo |
Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189. |
905 |
Czasopismo |
Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017. |
921 |
Czasopismo |
Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292. |
958 |
Czasopismo |
Vervloet E, Lammers J, Tan LSL, Van Mourik CH, Rots M. Netilmicin sulfate stability in combinaison with metronidazole or ranitidine hydrochloride in NaCl 0.9% infusion. Ann Pharmacotherapy 1990 ; 24: 440-442. |
999 |
Czasopismo |
Watson D. Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution. JPEN 1985 ; 9: 220-224. |
1022 |
Czasopismo |
Hutchinson SMW. Heparin and aminoglycosides instability. Drug Intell Clin Pharm 1986 ; 20: 886. |
1035 |
Czasopismo |
Bisaillon S, Sarrazin R. Compatibility of several antibiotics or hydrocortisone when added to metronidazole solution for intravenous infusion. J Parenter Sci Technol 1983 ; 37: 129-132. |
1200 |
Czasopismo |
Chaudry IA, Bruey KP, Hurlburt LE, Oden EM. Compatibility of netilmycin sulfate injection with commonly used intravenous injections and additives. Am J Hosp Pharm 1981 ; 38: 1737-1742. |
1236 |
Czasopismo |
Kuhn RJ, Nahata MC. Stability of netilmicin sulfate in admixtures with calcium gluconate and aminophylline. Am J Hosp Pharm 1986 ; 43: 1241-1242. |
1410 |
Czasopismo |
Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145. |
1415 |
Czasopismo |
Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74. |
1423 |
Czasopismo |
Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518. |
1754 |
Czasopismo |
Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244. |
1925 |
Czasopismo |
Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519. |
1929 |
Czasopismo |
Rigge DC, Jones MF. Shelf lives of aseptically prepared medicines - stability of netilmicin injection in polypropylene syringes. J Pharm Biomed Anal 2004 ; 35: 1251-1256. |
2296 |
Laboratorium |
Témocilline (Negaban®) - Résumé des caractéristiques du produit Eumedica 2017 |
3522 |
Laboratorium |
Flucloxacillin - Summary of Product Characteristics. Actavis 2013 |
3523 |
Laboratorium |
Ceftriaxone (Rocephin®) - Summary of Product Characteristics. Roche 2018 |
3526 |
Laboratorium |
Clindamycin (Dalacin®) - Summary of Product Characteristics Pharmacia 2010 |
3527 |
Laboratorium |
Amoxicillin (Amoxil®) – Summary of Product Characteristics Glaxo Smith Kline 2018 |
3540 |
Laboratorium |
Heparin sodium - Summary of Product Characteristics. Wockhardt 2010 |
3543 |
Laboratorium |
Ceftazidime – Summary of Product Characteristics Wockhardt 2013 |
3544 |
Laboratorium |
Cefoperazone (Cefobid®) - Summary of Product Characteristics Pfizer 2006 |
3545 |
Laboratorium |
Amoxicilline / acide clavulanique - Résumé des caractéristiques du produit Mylan SAS 2009 |
3546 |
Laboratorium |
Cefamandole Flavelab - Résumé des caractéristiques du produit Panpharma SA 2007 |
3548 |
Laboratorium |
Cefepime (Maxipime®) - Summary of Product caracteristics. Bristol Myers Squibb 2007 |
3578 |
Laboratorium |
Cisplatin - Summary of Product Characteristics Accord Healthcare 2011 |
3586 |
Laboratorium |
Piperacilline tazobactam Actavis® - Résumé des caractéristiques du produit Actavis France 2010 |
3587 |
Laboratorium |
Ticarcilline/acide clavulanique (Timentin®) - Summary of Product Characteristics GlaxoSmithKline 2014 |
3594 |
Laboratorium |
Metronidazole (Flagyl®) - Summary of Product Characteristics Zentiva 2013 |
3644 |
Laboratorium |
Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010 |
3656 |
Laboratorium |
Teicoplanine (Targocid®) - Résumé des caractéristiques du produit Sanofi Aventis France 2014 |
3674 |
Laboratorium |
Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016 |
3687 |
Laboratorium |
Cefuroxime sodium - Summary of Product Characteristics Stravencon 2013 |
3883 |
Laboratorium |
Ceftazidime - Résumé des caractéristiques du produit Arrow 2016 |